Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.32B |
| 2 |
AstraZeneca
AZN
|
+$733M |
| 3 |
Microsoft
MSFT
|
+$728M |
| 4 |
Cadence Design Systems
CDNS
|
+$720M |
| 5 |
Moody's
MCO
|
+$359M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$1.43B |
| 2 |
Estee Lauder
EL
|
+$872M |
| 3 |
Eli Lilly
LLY
|
+$626M |
| 4 |
Netflix
NFLX
|
+$521M |
| 5 |
UnitedHealth
UNH
|
+$466M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.19% |
| 2 | Consumer Discretionary | 19.62% |
| 3 | Healthcare | 16.16% |
| 4 | Financials | 9.12% |
| 5 | Communication Services | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Skyward Specialty Insurance
SKWD
$2.61B
| $11.2M | 0.01% |
+512,765
| New | +$9.96M |
|
377
EOG Resources
EOG
$71.5B
| $11.2M | 0.01% |
97,798
+456
| +0.5% | +$55.3K |
|
378
Concrete Pumping Holdings
BBCP
$490M
| $11.2M | 0.01% |
1,644,160
+4,858
| +0.3% | +$35.3K |
|
379
Outset Medical
OM
$96.6M
| $11.2M | 0.01% |
40,455
-227
| -0.6% | -$83.3K |
|
380
Nextpower Inc
NXT
$14.7B
| $11.1M | 0.01% |
+306,452
| New | +$9.7M |
|
381
CDW
CDW
$18.3B
| $11.1M | 0.01% |
56,859
+54,931
| +2,849% | +$10.8M |
|
|
ETRN
382
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $11.1M | 0.01% |
1,915,098
-1,343,804
| -41% | -$8.61M |
|
|
AXNX
383
DELISTED
Axonics, Inc. Common Stock
AXNX
| $11M | 0.01% |
201,326
+1,243
| +0.6% | +$72.6K |
|
384
Cameco
CCJ
$41B
| $10.9M | 0.01% |
418,175
+65,831
| +19% | +$1.74M |
|
|
AAMI
385
Acadian Asset Management
AAMI
$3.27B
| $10.9M | 0.01% |
461,836
-315,801
| -41% | -$7.43M |
|
386
Citi Trends
CTRN
$596M
| $10.9M | 0.01% |
571,912
+9,453
| +2% | +$260K |
|
387
Ameresco
AMRC
$1.37B
| $10.3M | 0.01% |
209,661
+17,337
| +9% | +$919K |
|
388
Definitive Healthcare
DH
$72.1M
| $10.3M | 0.01% |
993,253
-787,002
| -44% | -$9.27M |
|
389
Helios Technologies
HLIO
$2.72B
| $10.1M | 0.01% |
+154,847
| New | +$10.1M |
|
390
Grab
GRAB
$14.9B
| $9.98M | 0.01% |
3,315,882
-3,862,606
| -54% | -$12.8M |
|
391
Baidu
BIDU
$36.9B
| $9.9M | 0.01% |
+65,616
| New | +$9.31M |
|
392
Protagonist Therapeutics
PTGX
$9.41B
| $9.87M | 0.01% |
+428,938
| New | +$7.2M |
|
393
New Fortress Energy
NFE
$96.3M
| $9.68M | 0.01% |
328,937
+71,037
| +28% | +$2.5M |
|
394
Azenta
AZTA
$1.43B
| $9.67M | 0.01% |
216,796
+1,092
| +0.5% | +$54.1K |
|
395
Structure Therapeutics
GPCR
$3.68B
| $9.51M | 0.01% |
+399,780
| New | +$9.39M |
|
396
J.M. Smucker
SJM
$12.7B
| $9.31M | 0.01% |
59,186
+51,593
| +679% | +$7.84M |
|
|
NOVA
397
DELISTED
Sunnova Energy
NOVA
| $9.26M | 0.01% |
592,896
-1,893
| -0.3% | -$33.1K |
|
398
Corning
GLW
$136B
| $9.14M | 0.01% |
259,072
-103,891
| -29% | -$3.61M |
|
399
SBA Communications
SBAC
$19.4B
| $9.09M | 0.01% |
34,820
-158,725
| -82% | -$43.7M |
|
400
CF Industries
CF
$17.8B
| $8.95M | 0.01% |
123,456
-97,730
| -44% | -$7.99M |
|
Similar funds
Jennison Associates's Q1 2023 Portfolio in Review
As of Q1 2023, Jennison Associates held 644 positions worth $109B, up 10% from $98.7B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Jennison Associates withdrew a net $3.94B in Q1 2023, closing 63 positions and reducing 280 holdings. Its most notable exit was Alcon, an estimated $1.43B position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $1.59B.
- Jennison Associates's largest Q1 2023 buy was Advanced Micro Devices: 16,272,765 shares worth $1.59B.
- Jennison Associates added most to AstraZeneca in Q1 2023, an estimated $733M increase.
- Jennison Associates's biggest Q1 2023 reduction was Estee Lauder, cutting an estimated $872M.
- Jennison Associates fully exited Alcon in Q1 2023, selling an estimated $1.43B.
- Jennison Associates's ten largest holdings make up 39% of its $109B portfolio in Q1 2023.
- Jennison Associates opened 73 new positions and closed 63 in Q1 2023.
- Jennison Associates's portfolio value rose 10% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.